spacer
home > pmps > winter 2001 > editor's letter
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Editor's Letter

This year has been a milestone - the first year of the millennium has been overshadowed by the tragic events of September 11th, followed by the war in Afghanistan. These events have had their impact on our industry in at least two ways. Firstly, many visitors and exhibitors to the events planned in October were unable to travel. As a result, for our US colleagues in particular, planned meetings didn't happen.

Nevertheless, it was interesting to see many of the European and Asia Pacific contract pharmaceutical manufacturers and suppliers at the CPhI in London. Secondly, the increased threat of bioterrorism focused the minds of pharma and biotech players and their investors in the scramble for dwindling stocks of antibiotics effective against anthrax, while orders for the

smallpox vaccine by the US government have been of benefit to UK suppliers. In the biotech sector, companies may be looking further ahead to anticipate their leading edge technologies being overtaken. Formation of alliances, partnerships or M&As could be part of a defensive strategy.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Along with our sister publications, EBR and EPC, this issue of PMPS is published by our new owners Samedan Ltd. PMPS Winter 2001 aims to provide interesting reading over the festive season.
spacer
Dr Patricia Lobo
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

MedPharm announce expansion of partnership with Palvella Therapeutics in developing a new treatment for the debilitating rare disease, pachyonychia congenita

MedPharm Ltd have announced the expansion of their partnership with Palvella Therapeutics, Inc., a Philadelphia-based biopharmaceutical company focused on developing and commercialising therapies for debilitating, rare genetic diseases. To date, MedPharm has employed its world-renowned specialist formulation expertise to support Palvella’s development of a novel, high-strength rapamycin topical formulation for application to the skin (PTX 022) as a disease-modifying treatment for pachyonychia congenita (PC). Most recently, MedPharm has made arrangements to manufacture the clinical (IMP) batches for use in Palvella’s upcoming Phase 2/3 clinical study.
More info >>

White Papers

Backward Thinking

Development of a generic equivalent to a current marketed pressurized metered dose inhaler (pMDI) product brings immense challenges. Thorough analysis is critical to gain a comprehensive understanding of the physical attributes and pharmaceutical performance of the reference marketed product. Many factors need to be assessed, understood and combined in order to successfully develop a generic pMDI which will meet the regulatory and quality requirements as an equivalent product in the anticipated target market.
More info >>

 
Industry Events

DIA 2019 Global Annual Meeting

23-27 June 2019, San Diego Convention Center

DIA 2019 is more than just a meeting: it’s where brilliant minds come together to create solutions. Thousands of global innovators will convene to engage in discussions on today’s hottest topics in the life sciences field, propose ways to combat daily challenges, and network to create lasting connections.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement